Supriya Lifescience Limited is planning a capex program at Ambernath site with an estimated aggregate capital outlay of INR 60 million over the next 3 years. The Board of Directors, at their meeting held on February 7, 2024 has initially approved capital expenditure of approx. INR 60 million for site development and related infrastructure on approx.

5000 sq mtr. of land for project at Ambernath. The said capital expenditure would be majorly funded by the Company out of its internal accruals.

The development of this factory will enable the Company to set up facility required for various CDMO projects.